An analysis by Haleon plc researchers is critical of the US drug industry and the Food and Drug Administration’s record for Rx-to-OTC switches during the past 20 years, finding that “an overwhelming majority” didn’t add innovative products to the consumer health care marketplace.
The analysis published earlier in June in the journal Therapeutic Innovation & Regulatory Science, which authors Matt Fisher and Kapil...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?